Advertisement

Annals of Hematology

, Volume 97, Issue 3, pp 435–441 | Cite as

Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation

  • Andrew T. Kuykendall
  • Savan Shah
  • Chetasi Talati
  • Najla Al Ali
  • Kendra Sweet
  • Eric Padron
  • David A. Sallman
  • Jeffrey E. Lancet
  • Alan F. List
  • Kenneth S. Zuckerman
  • Rami S. Komrokji
Original Article

Abstract

Ruxolitinib is a JAK1/2 inhibitor that is effective in managing symptoms and splenomegaly related to myelofibrosis (MF). Unfortunately, many patients must discontinue ruxolitinib, at which time treatment options are not well defined. In this study, we investigated salvage treatment options and clinical outcomes among MF patients who received and discontinued ruxolitinib outside the context of a clinical trial. Among 145 patients who received ruxolitinib, 23 died while on treatment, 58 remained on treatment at time of analysis, leaving 64 people available for analysis. Development of cytopenias was the most common reason for discontinuation (38%) after median treatment time of 3.8 months (mo). The majority of patients received some form of salvage therapy after ruxolitinib discontinuation (n = 42; 66%), with allogeneic hematopoietic stem cell transplant (alloHSCT) (n = 17), being most commonly employed. Lenalidomide, thalidomide, hydroxyurea, interferon, and danazol were used with similar frequency. The response rate to salvage treatment was 26% (8 responses) and responses were most often seen with lenalidomide or thalidomide. Improved outcomes were observed in patients who underwent alloHSCT or received salvage therapy compared to those who did not receive additional therapy. Median overall survival (OS) after ruxolitinib discontinuation was 13 months. These findings show that salvage therapy can provide clinical responses after ruxolitinib discontinuation; however, these responses are rare and outcomes in this patient population are poor. This represents an area of unmet clinical need in MF.

Keywords

Ruxolitinib Myelofibrosis 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799–807.  https://doi.org/10.1056/NEJMoa1110557 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Harrison C, Kiladjian JJ, al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787–798.  https://doi.org/10.1056/NEJMoa1110556 CrossRefPubMedGoogle Scholar
  3. 3.
    Passamonti F, Maffioli M, Cervantes F, Vannucchi AM, Morra E, Barbui T, Caramazza D, Pieri L, Rumi E, Gisslinger H, Knoops L, Kiladjian JJ, Mora B, Hollaender N, Pascutto C, Harrison C, Cazzola M (2014) Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood 123(12):1833–1835.  https://doi.org/10.1182/blood-2013-12-544411 CrossRefPubMedGoogle Scholar
  4. 4.
    Harrison CN, Vannucchi AM, Kiladjian JJ, al-Ali HK, Gisslinger H, Knoops L, Cervantes F, Jones MM, Sun K, McQuitty M, Stalbovskaya V, Gopalakrishna P, Barbui T (2016) Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 30(8):1701–1707.  https://doi.org/10.1038/leu.2016.148 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MWN, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H, For the COMFORT-I investigators (2015) Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica 100(4):479–488.  https://doi.org/10.3324/haematol.2014.115840 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S, on behalf of the COMFORT Investigators (2015) A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica 100(9):1139–1145.  https://doi.org/10.3324/haematol.2014.119545 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Mesa RA, Verstovsek S, Gupta V, Mascarenhas JO, Atallah E, Burn T, Sun W, Sandor V, Gotlib J (2015) Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. Clin Lymphoma Myeloma Leuk 15(4):214–221 e1.  https://doi.org/10.1016/j.clml.2014.12.008 CrossRefPubMedGoogle Scholar
  8. 8.
    Kuykendall AT, Talati C, al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS (2017. [In Press) The treatment landscape of myelofibrosis before and after ruxolitinib approval. Clin Lymphoma Myeloma Leuk 17(12):e45–e53.  https://doi.org/10.1016/j.clml.2017.08.002 CrossRefPubMedGoogle Scholar
  9. 9.
    Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, Bose P, Daver N, Cortes J, Kantarjian H, Verstovsek S (2017) Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood 130(9):1125–1131.  https://doi.org/10.1182/blood-2017-05-783225 CrossRefPubMedGoogle Scholar
  10. 10.
    Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405.  https://doi.org/10.1182/blood-2016-03-643544 CrossRefPubMedGoogle Scholar
  11. 11.
    Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B, Levine R, le Bousse-Kerdiles MC, Wadleigh M, Campbell PJ, Silver RT, Vannucchi AM, Deeg HJ, Gisslinger H, Thomas D, Odenike O, Solberg LA, Gotlib J, Hexner E, Nimer SD, Kantarjian H, Orazi A, Vardiman JW, Thiele J, Tefferi A, International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) (2007) Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 31(6):737–740.  https://doi.org/10.1016/j.leukres.2006.12.002 CrossRefPubMedGoogle Scholar
  12. 12.
    Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22(1):14–22.  https://doi.org/10.1038/sj.leu.2404955 CrossRefPubMedGoogle Scholar
  13. 13.
    Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, Guglielmelli P, Pungolino E, Caramella M, Maffioli M, Pascutto C, Lazzarino M, Cazzola M, Tefferi A (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115(9):1703–1708.  https://doi.org/10.1182/blood-2009-09-245837 CrossRefPubMedGoogle Scholar
  14. 14.
    Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, Gotlib J, Dupriez B, Pardanani A, Harrison C, Hoffman R, Gisslinger H, Kroger N, Thiele J, Barbui T, Barosi G (2013) Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 122(8):1395–1398.  https://doi.org/10.1182/blood-2013-03-488098
  15. 15.
    Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895–2901.  https://doi.org/10.1182/blood-2008-07-170449 CrossRefPubMedGoogle Scholar
  16. 16.
    Fauble V, Leis J, Mesa RA (2012) Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors. Leuk Suppl 1(Suppl 1):S2–S7.  https://doi.org/10.1038/leusup.2012.2 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Jung CW (2013) Ruxolitinib changes the natural course of myelofibrosis and its transplant outcome. Blood Res 48(1):68–69.  https://doi.org/10.5045/br.2013.48.1.68 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Jaekel N, Behre G, Behning A, Wickenhauser C, Lange T, Niederwieser D, al-Ali HK (2014) Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transplant 49(2):179–184.  https://doi.org/10.1038/bmt.2013.173 CrossRefPubMedGoogle Scholar
  19. 19.
    Stubig T et al (2014) JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. Leukemia 28(8):1736–1738.  https://doi.org/10.1038/leu.2014.86
  20. 20.
    Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring JM, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG, Hanif A, Champlin R, Hari P, Gupta V (2016) Outcomes of allogeneic hematopoietic cell transplantation in patients with Myelofibrosis with prior exposure to Janus kinase 1/2 inhibitors. Biol Blood Marrow Transplant 22(3):432–440.  https://doi.org/10.1016/j.bbmt.2015.10.005 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Authors and Affiliations

  • Andrew T. Kuykendall
    • 1
  • Savan Shah
    • 2
  • Chetasi Talati
    • 1
  • Najla Al Ali
    • 3
  • Kendra Sweet
    • 3
  • Eric Padron
    • 3
  • David A. Sallman
    • 3
  • Jeffrey E. Lancet
    • 3
  • Alan F. List
    • 3
  • Kenneth S. Zuckerman
    • 3
  • Rami S. Komrokji
    • 3
  1. 1.University of South Florida Morsani College of Medicine at H. Lee Moffitt Cancer CenterTampaUSA
  2. 2.Morsani College of Medicine, Department of Internal MedicineUniversity of South FloridaTampaUSA
  3. 3.Department of Malignant HematologyH. Lee Moffitt Cancer Center and Research InstituteTampaUSA

Personalised recommendations